<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:department>Dept of Chemistry</gtr:department><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/D5097EFF-DD66-450A-AECD-ABF9361B3B7A"><gtr:id>D5097EFF-DD66-450A-AECD-ABF9361B3B7A</gtr:id><gtr:firstName>James</gtr:firstName><gtr:otherNames>Adam</gtr:otherNames><gtr:surname>Bull</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=EP%2FJ001538%2F1"><gtr:id>C7314FAA-EFEB-4547-87E8-FF1C22D58A50</gtr:id><gtr:title>Novel strategies to access chiral heterocycles as potential lead compounds in drug discovery</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>EP/J001538/1</gtr:grantReference><gtr:abstractText>The development of new medicines (drug discovery) is essential to improve the health of the world's population. Tackling current medical needs requires drugs that will work in new ways. Therefore, more complex biological interactions are being investigated as targets. However, finding good starting points for drug development that will act against these complex biological targets presents a formidable challenge.

Historically, starting points for drug development, known as lead compounds, came from natural small molecules that bind to the target. However, these are often not available, particularly in complex binding interactions. The screening of compound collections in the pharmaceutical industry has also been largely unsuccessful in finding lead compounds for more complex targets. This is because industrial compound collections are often clustered around relatively few structural types and are frequently reliant on flat (non-chiral) structures. Alternative methods are required for the generation of more diverse and 3-dimensional (chiral) molecules that may function as drug-leads. Indeed the pharmaceutical industry is currently interested in focussing on fewer, higher quality lead compounds.

This research will develop new chemical methods to enable the synthesis of diverse molecular frameworks with the potential to be lead compounds in drug discovery. These frameworks will be centred around chiral (3-D) heterocycles. Heterocycles are carbon based ring structures that contain at least one heteroatom in the ring (i.e. an oxygen, nitrogen or sulphur atom) and are frequently essential components of drug compounds. Chiral heterocycles in particular offer ideal properties for quality lead compounds, being small with desirable physical properties as well as having a defined 3- dimensional shape, which is crucial to structural and binding interactions with biological systems.

The synthesis of these complex heterocyclic molecules from simple, readily available starting materials is of fundamental interest and a major synthetic challenge. The key synthetic innovation of this proposal is the invention, development and application of new chemical reagents to achieve this goal. These reagents contain multiple functionality, important in performing multiple roles in the synthesis. Synthetic methods will be developed for three classes of chiral heterocycles with control of the 3-D shape. Furthermore these synthetic methods will allow a wide variety of chemical groups to be introduced directly onto the heterocyclic core of the molecule. This will enable rapid access to diverse molecular frameworks not currently well represented in industrial compound collections.

Compounds generated by these new methods are of interest as potential lead compounds against a wide variety of biological targets. To demonstrate this, a series of analogues will be prepared of a compound known to disrupt the interaction between two proteins that is implicated in various types of cancer. Future collaborative research is envisaged to evaluate the now accessible compounds against biological targets. Furthermore, the new chemical reagents and the synthetic methods developed in this research will be widely applicable in fields of chemical synthesis and medicinal chemistry.</gtr:abstractText><gtr:potentialImpactText>The pharmaceutical and agrochemical industries in the UK are expected to be the most significant beneficiaries. The pharmaceutical industry is in a period of upheaval due to failure of drugs to get to market and loss of patent protection on blockbuster drugs. This, combined with the failure of screening collections against emerging targets makes new approaches to the development of quality screening collections a pressing endeavour. Furthermore there is increasing demand for novel chemical libraries to identify biologically active targets to match the rapid advances in genomic and proteomic approaches. 

The following outcomes of the research may have impact for these beneficiaries:
i) Synthetic strategy:
The strategies developed by this research will provide new approaches to the preparation of compound types desirable for their biological activity. It will provide flexibility to introduce a diverse array of substituents directly onto the heterocyclic core to provide both framework diversity and structural complexity hence enabling rapid access to areas of unknown bioactive chemical space, not accessed by traditional libraries. 
ii) Improved methods to access desirable structural types:
The beneficiaries may take advantage of the specific methodology developed by this research to access structural types that are currently desirable in medicinal chemistry but that do not have efficient methods for their preparation. 
iii) The compounds themselves:
Testing of the diverse arrays of compounds generated by this research may lead to interesting biological activity or lead-compounds for further development. This may be achieved by direct collaboration with industry or through academic collaboration leading to future industry collaboration. For example Lilly provide phenotypic screens offered without charge, which focus on compounds of novel structural diversity, for which these structures would be relevant candidates.
iv) Reagents as generally applicable in synthetic chemistry:
Reagents developed in this research and the increased understanding of their reactivity may find broader use in synthetic chemistry by industry scientists in alternative synthetic programmes, in the discovery or development stages of a drug discovery programme. 

The increased regulatory pressure and pressure on pricing by healthcare systems means that increased efficiency is vital in terms of time, resources and waste. The chemistry developed here will allow ease of initial synthesis and subsequent ease of structural optimisation, providing a strategic advantage in medicinal chemistry research where extensive iterative analogue synthesis is required. This will reduce the time required for discovery, the number of synthetic operations and the cost leading to positive economic and environmental impacts. Increased efficiency in drug development would provide lower cost healthcare to government healthcare systems and the patients. Ultimately, through any of these avenues this research may aid in the successful development and commercialisation of a drug compound, which would be beneficial to the UK economy. New drug compounds would be beneficial to the health and well being of the UK population. 

The successful development of novel and efficient synthetic routes to these ring structures and methods of functionalisation may lead to patentable results or procedures and further development through licensing. The research contributions of the PhD students will make them well placed for professional contribution to the UK pharmaceutical or agrochemical industries.</gtr:potentialImpactText><gtr:fund><gtr:end>2015-12-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/798CB33D-C79E-4578-83F2-72606407192C"><gtr:id>798CB33D-C79E-4578-83F2-72606407192C</gtr:id><gtr:name>EPSRC</gtr:name></gtr:funder><gtr:start>2011-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>723115</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>28500</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CASE: 4-Ring Boronic Acids (AstraZeneca)</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>AstraZeneca</gtr:fundingOrg><gtr:id>57300C21-BEFF-4B74-8D7A-81F6B7559789</gtr:id><gtr:outcomeId>r-9126689032.769472068bba28</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>14870</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Royal Society Research Grant</gtr:description><gtr:end>2015-02-02</gtr:end><gtr:fundingOrg>The Royal Society</gtr:fundingOrg><gtr:id>042B5770-21CE-4E8D-BFEE-5AD591E24A36</gtr:id><gtr:outcomeId>545e411e95d796.60494943</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>31500</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CASE: Fragment-like and Lead-like Screening Collections (Lilly)</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Eli Lilly &amp; Company Ltd</gtr:fundingOrg><gtr:id>E2EA67EA-269D-4D50-BF96-F6B0A8E309B4</gtr:id><gtr:outcomeId>r-8536222175.263075068aabec</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>53195</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Impact Acceleration: Pathways to Impact Funding</gtr:description><gtr:end>2015-09-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:id>B4E09417-3311-4E0D-BE24-B557A1A27A6E</gtr:id><gtr:outcomeId>545e402776e236.63123904</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>20000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Collaboration kick start funding (Ullman Arylation)</gtr:description><gtr:end>2015-06-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:id>235CA51C-DE28-49D9-9E64-45CC81455431</gtr:id><gtr:outcomeId>545e408339cc86.54977321</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>30000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CASE: Ullmann coupling (AstraZeneca)</gtr:description><gtr:end>2018-03-02</gtr:end><gtr:fundingOrg>AstraZeneca</gtr:fundingOrg><gtr:id>9FEC049A-D984-4EE1-8FCD-C983F0F5965F</gtr:id><gtr:outcomeId>545e3f977e6d67.84516604</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2014-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>108580</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>iCASE (EPSRC/AstraZeneca)</gtr:description><gtr:end>2020-09-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:id>BD927668-F079-4374-9472-0EA1E52E601D</gtr:id><gtr:outcomeId>56ce58ae724ae3.65156497</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>30000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Pharmacat Consortium</gtr:department><gtr:description>Pharmacat Funded MRes/PhD</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Imperial College London</gtr:fundingOrg><gtr:id>8D59143F-3C88-4303-92EE-E3BD705A6D8B</gtr:id><gtr:outcomeId>r-3549027585.935804406888524</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>493467</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>University Research Fellowship</gtr:description><gtr:end>2022-12-02</gtr:end><gtr:fundingOrg>The Royal Society</gtr:fundingOrg><gtr:id>76463667-25F5-4261-9FEA-0A1A149A902A</gtr:id><gtr:outcomeId>56ce57954a2278.17489077</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>19975</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Collaboration kick start funding (Amide formation)</gtr:description><gtr:end>2013-06-02</gtr:end><gtr:fundingOrg>Engineering and Physical Sciences Research Council (EPSRC)</gtr:fundingOrg><gtr:id>A10A8467-ABEF-45F4-8384-FD79EF74FC2F</gtr:id><gtr:outcomeId>5edd86c05edd86d4</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>The CAF award has developed strategies for the preparation of biologically relevant compounds as well as generating a collection of novel compounds. The methods and new compound types generated have interest in the medicinal chemistry community. Dr Bull has presented results to a wide variety of industrial audiences, giving invited lectures at Eli Lilly, Syngenta, UCB, Vertex, GSK, Sygnature. New collaborations have commenced with AstraZeneca, Pfizer, Eli Lilly and GSK. 

The compounds themselves have been exploited by testing for biological activity with collaborators. In particular, Dr Bull collaborated with Eli Lilly through the Open Innovation Drug Discovery programme. In 2015 Dr Bull was awarded the Eli Lilly OIDD Award for Outstanding Contribution to Compound Screening. In addition, numerous compounds were tested through the Co-Add initiative (Community for Open Antimicrobial Drug Discovery), generating preliminary hits for antimicrobial activity.</gtr:description><gtr:firstYearOfImpact>2015</gtr:firstYearOfImpact><gtr:id>5B736A14-C721-4E80-9569-D162F253440F</gtr:id><gtr:impactTypes><gtr:impactType>Societal</gtr:impactType></gtr:impactTypes><gtr:outcomeId>56dd706b497749.62488435</gtr:outcomeId><gtr:sector>Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>This Fellowship grant has resulted in new chemical methods to enable the synthesis of diverse molecular frameworks with the potential to be lead compounds in drug discovery. These frameworks were centred around chiral (3-D) heterocycles and designed to possess desirable physicochemical properties for biological screening, and for to be suitable for further derivatisation. New strategies for the synthesis and catalytic derivatisation of novel small ring containing compounds have been developed for each of the proposed heterocyclic targets.
One of the most prominent areas of work was the synthesis of oxetanes. Oxetanes have become extremely attractive motifs in drug discovery. We have made significant contributions in this field through our development of a new strategy in oxetane synthesis via C-C bond forming cyclisation. New oxetane motifs with little structural precedent were designed and successfully prepared via our new approach. This has allowed the introduction of a much wider array of medicinally relevant functional groups onto the ring, accessing new chemical space. Having established the synthetic concepts, the applicability to medicinal chemistry of some of the oxetane derivatives was determined in with collaboration with AstraZeneca, particularly the stability to acidic media and metabolic enzymes 
Additionally, new catalytic technology for the derivatisation of various other heterocycle classes (including pyrrolidine, THF, imidazoline, aziridine) has been developed. Notably the CH functionalisation of nitrogen and oxygen heterocycles at unactivated positions has been achieved. All of the original objectives have been met, and numerous additional projects have commenced based on results from this work

Each of the proposed structural types have been developed, and we are now further developing these to larger collections of compounds. With collaborators we have assessed novel compounds against disease targets, and also for stability to biological conditions.</gtr:description><gtr:exploitationPathways>We are continuing to work with a number of pharmaceutical companies. We have developed collaborations with AstraZeneca (UK), Eli Lilly (UK), and Pfizer (US) to develop further synthetic methods towards small ring synthesis, and new motifs with medicinal chemistry appeal, and to exploit these in medicinal chemistry.</gtr:exploitationPathways><gtr:id>FD3EB056-92C7-441C-9F4F-087626B04E5F</gtr:id><gtr:outcomeId>56dd86ce4c9f00.77480738</gtr:outcomeId><gtr:sectors><gtr:sector>Chemicals,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>5F24986F-2E6D-4A59-9FB9-D7A40CECF932</gtr:id><gtr:title>Synthesis of diversely functionalised 2,2-disubstituted oxetanes: fragment motifs in new chemical space.</gtr:title><gtr:parentPublicationTitle>Chemical communications (Cambridge, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/acf61823046f179239525d42b6e64e65"><gtr:id>acf61823046f179239525d42b6e64e65</gtr:id><gtr:otherNames>Davis OA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1359-7345</gtr:issn><gtr:outcomeId>5675eb2caf027</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9A7892F7-0E40-408B-B931-885142214C22</gtr:id><gtr:title>2-(Aryl-sulfonyl)oxetanes as designer 3-dimensional fragments for fragment screening: synthesis and strategies for functionalisation.</gtr:title><gtr:parentPublicationTitle>Chemical communications (Cambridge, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/74cf5226e1195c16ad4c8ff5308f9e22"><gtr:id>74cf5226e1195c16ad4c8ff5308f9e22</gtr:id><gtr:otherNames>Morgan KF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1359-7345</gtr:issn><gtr:outcomeId>5675d919624fb</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BA636ED7-3902-40E4-BE1E-0240EE08991F</gtr:id><gtr:title>Catalytic enantioselective synthesis of secondary alkylboronate building blocks with and without metals.</gtr:title><gtr:parentPublicationTitle>Angewandte Chemie (International ed. in English)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b818cb8cad4736464601bdfa213937df"><gtr:id>b818cb8cad4736464601bdfa213937df</gtr:id><gtr:otherNames>Bull JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1433-7851</gtr:issn><gtr:outcomeId>doi_53cfc1fc18831276</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2CC8DBBA-4E68-406C-A767-C64B5CDEC971</gtr:id><gtr:title>Recent Advances in the Synthesis of 2-Substituted Oxetanes</gtr:title><gtr:parentPublicationTitle>Synlett</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dcac379850bf6c130d6b2213a51fb383"><gtr:id>dcac379850bf6c130d6b2213a51fb383</gtr:id><gtr:otherNames>Bull J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>5675f536bfec6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BC630BBF-ADBE-494D-AE89-659048D67AF1</gtr:id><gtr:title>Studies on the synthesis of a-iodoaziridines and improved conditions for the synthesis of alkyl-a-iodoaziridines using ClMgCHI2</gtr:title><gtr:parentPublicationTitle>Tetrahedron</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/63d943c394d45a59ccfe93101e7c5cd4"><gtr:id>63d943c394d45a59ccfe93101e7c5cd4</gtr:id><gtr:otherNames>Boultwood T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>5675ee0cceafa</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>39387912-D5D9-481B-8D55-A09A3AE27B5E</gtr:id><gtr:title>Synthesis of cis-C-iodo-N-tosyl-aziridines using diiodomethyllithium: reaction optimization, product scope and stability, and a protocol for selection of stationary phase for chromatography.</gtr:title><gtr:parentPublicationTitle>The Journal of organic chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/63d943c394d45a59ccfe93101e7c5cd4"><gtr:id>63d943c394d45a59ccfe93101e7c5cd4</gtr:id><gtr:otherNames>Boultwood T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-3263</gtr:issn><gtr:outcomeId>doi_53d01801871cef07</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FC82874C-9B3E-47A1-A60B-7C1D60D0706D</gtr:id><gtr:title>Oxetanes: Recent Advances in Synthesis, Reactivity, and Medicinal Chemistry.</gtr:title><gtr:parentPublicationTitle>Chemical reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b818cb8cad4736464601bdfa213937df"><gtr:id>b818cb8cad4736464601bdfa213937df</gtr:id><gtr:otherNames>Bull JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0009-2665</gtr:issn><gtr:outcomeId>585d71d086b528.27753400</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EA8C918C-9DC9-4067-B99E-81A08A346D86</gtr:id><gtr:title>Regio- and stereospecific synthesis of C-3 functionalized proline derivatives by palladium catalyzed directed C(sp3)-H arylation.</gtr:title><gtr:parentPublicationTitle>Organic letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/15d1428ea3ac5763108312abefd554c6"><gtr:id>15d1428ea3ac5763108312abefd554c6</gtr:id><gtr:otherNames>Affron DP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1523-7052</gtr:issn><gtr:outcomeId>545e3b863cf461.31425245</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D814AA14-4D1A-4BE9-95B4-97BB9C6DBAD6</gtr:id><gtr:title>Transfer of Electrophilic NH Using Convenient Sources of Ammonia: Direct Synthesis of NH Sulfoximines from Sulfoxides.</gtr:title><gtr:parentPublicationTitle>Angewandte Chemie (International ed. in English)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0e87236935bee633296c2ece33d22e81"><gtr:id>0e87236935bee633296c2ece33d22e81</gtr:id><gtr:otherNames>Zenzola M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1433-7851</gtr:issn><gtr:outcomeId>585d5a7b20f588.23259278</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>46F92072-6CB0-4D38-B239-ACBCBFA3393D</gtr:id><gtr:title>Copper-catalyzed N-arylation of 2-imidazolines with aryl iodides.</gtr:title><gtr:parentPublicationTitle>The Journal of organic chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/acf61823046f179239525d42b6e64e65"><gtr:id>acf61823046f179239525d42b6e64e65</gtr:id><gtr:otherNames>Davis OA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-3263</gtr:issn><gtr:outcomeId>doi_53d018018713646f</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3D6A73A0-4489-48FF-868E-332A42E79AA0</gtr:id><gtr:title>Transfer of Electrophilic NH Using Convenient Sources of Ammonia: Direct Synthesis of NH Sulfoximines from Sulfoxides</gtr:title><gtr:parentPublicationTitle>Angewandte Chemie</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0e87236935bee633296c2ece33d22e81"><gtr:id>0e87236935bee633296c2ece33d22e81</gtr:id><gtr:otherNames>Zenzola M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>585d592015f668.53573757</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A5927778-EF88-41A2-AFD6-3D3CB375BCAB</gtr:id><gtr:title>Synthesis of Substituted 1,4-Dioxenes through O-H Insertion and Cyclization Using Keto-Diazo Compounds.</gtr:title><gtr:parentPublicationTitle>The Journal of organic chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/acf61823046f179239525d42b6e64e65"><gtr:id>acf61823046f179239525d42b6e64e65</gtr:id><gtr:otherNames>Davis OA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-3263</gtr:issn><gtr:outcomeId>585d73263c2468.56492129</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7A24F9FD-6C27-48ED-8AE9-8832FC051542</gtr:id><gtr:title>Palladium-catalyzed cross-coupling of aziridinylmetal species, generated by sulfinyl-magnesium exchange, with aryl bromides: reaction optimization, scope, and kinetic investigations.</gtr:title><gtr:parentPublicationTitle>The Journal of organic chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/61f0cf0f16d76c3fe54012bce667060a"><gtr:id>61f0cf0f16d76c3fe54012bce667060a</gtr:id><gtr:otherNames>Hughes M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-3263</gtr:issn><gtr:outcomeId>doi_53d0180186fe49f1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>036992EE-243C-4B18-9174-8B855B9932BD</gtr:id><gtr:title>Synthesis and purification of iodoaziridines involving quantitative selection of the optimal stationary phase for chromatography.</gtr:title><gtr:parentPublicationTitle>Journal of visualized experiments : JoVE</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/63d943c394d45a59ccfe93101e7c5cd4"><gtr:id>63d943c394d45a59ccfe93101e7c5cd4</gtr:id><gtr:otherNames>Boultwood T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1940-087X</gtr:issn><gtr:outcomeId>545e3a74585742.04877769</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>88AC481E-8C2A-40F3-8332-B9567BEBCC73</gtr:id><gtr:title>Synthesis of di-, tri-, and tetrasubstituted oxetanes by rhodium-catalyzed O-H insertion and C-C bond-forming cyclization.</gtr:title><gtr:parentPublicationTitle>Angewandte Chemie (International ed. in English)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/acf61823046f179239525d42b6e64e65"><gtr:id>acf61823046f179239525d42b6e64e65</gtr:id><gtr:otherNames>Davis OA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1433-7851</gtr:issn><gtr:outcomeId>545e3c15efaaf5.04714910</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D7C58F49-271C-4661-A21F-D82A3B2A8049</gtr:id><gtr:title>Synthesis of Sulfoximine Carbamates by Rhodium-Catalyzed Nitrene Transfer of Carbamates to Sulfoxides.</gtr:title><gtr:parentPublicationTitle>The Journal of organic chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0e87236935bee633296c2ece33d22e81"><gtr:id>0e87236935bee633296c2ece33d22e81</gtr:id><gtr:otherNames>Zenzola M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-3263</gtr:issn><gtr:outcomeId>5675e4c2abefd</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E6A42E75-CCAD-4B62-A48F-1B6C5C209C37</gtr:id><gtr:title>Single operation palladium catalysed C(sp)-H functionalisation of tertiary aldehydes: investigations into transient imine directing groups.</gtr:title><gtr:parentPublicationTitle>Chemical science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/31134fe0c8a443a431e7a4a92d2e4928"><gtr:id>31134fe0c8a443a431e7a4a92d2e4928</gtr:id><gtr:otherNames>St John-Campbell S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2041-6520</gtr:issn><gtr:outcomeId>5a35290cc51219.15098708</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C2151BD4-6E94-4DA7-AF2E-EE010EE6A457</gtr:id><gtr:title>Imaging phase separation in model lipid membranes through the use of BODIPY based molecular rotors.</gtr:title><gtr:parentPublicationTitle>Physical chemistry chemical physics : PCCP</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9be606b80e7e8b148094ee3bc6d8bf14"><gtr:id>9be606b80e7e8b148094ee3bc6d8bf14</gtr:id><gtr:otherNames>Dent MR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1463-9076</gtr:issn><gtr:outcomeId>5675e723dd7c0</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CFD8C3B8-048A-4C8B-8440-B8D5604127D1</gtr:id><gtr:title>Divergent Synthesis of Cyclopropane-Containing Lead-Like Compounds, Fragments and Building Blocks through a Cobalt Catalyzed Cyclopropanation of Phenyl Vinyl Sulfide.</gtr:title><gtr:parentPublicationTitle>European journal of organic chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/040d002bf0c5c58aa3bfd1b98cdafc8f"><gtr:id>040d002bf0c5c58aa3bfd1b98cdafc8f</gtr:id><gtr:otherNames>Chawner SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1099-0690</gtr:issn><gtr:outcomeId>5a2fe4b67a7054.15365774</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>25153B82-5672-4660-9422-7D9E4BE84759</gtr:id><gtr:title>2-Sulfinyl Oxetanes: Synthesis, Stability and Reactivity</gtr:title><gtr:parentPublicationTitle>Synlett</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dcac379850bf6c130d6b2213a51fb383"><gtr:id>dcac379850bf6c130d6b2213a51fb383</gtr:id><gtr:otherNames>Bull J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56a8be936decb7.56417036</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EF14C030-52EC-46A3-B6D2-8A55BB8A11D9</gtr:id><gtr:title>Palladium-Catalyzed Directed C(sp)-H Arylation of Saturated Heterocycles at C-3 Using a Concise Optimization Approach.</gtr:title><gtr:parentPublicationTitle>European journal of organic chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/15d1428ea3ac5763108312abefd554c6"><gtr:id>15d1428ea3ac5763108312abefd554c6</gtr:id><gtr:otherNames>Affron DP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1099-0690</gtr:issn><gtr:outcomeId>56a8be93411514.40104038</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>13DC27F2-8710-4DD3-8283-2F8E451A9B70</gtr:id><gtr:title>Highly cis-selective synthesis of iodo-aziridines using diiodomethyllithium and in situ generated N-Boc-imines.</gtr:title><gtr:parentPublicationTitle>Chemical communications (Cambridge, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b818cb8cad4736464601bdfa213937df"><gtr:id>b818cb8cad4736464601bdfa213937df</gtr:id><gtr:otherNames>Bull JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1359-7345</gtr:issn><gtr:outcomeId>56dd8f752faf92.01092422</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AE7111DB-B71D-45B8-87C2-DF4097BA1BB5</gtr:id><gtr:title>Stereospecific functionalization of iodoaziridines via unstabilized aziridinyllithiums generated by iodine-lithium exchange.</gtr:title><gtr:parentPublicationTitle>Organic letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/63d943c394d45a59ccfe93101e7c5cd4"><gtr:id>63d943c394d45a59ccfe93101e7c5cd4</gtr:id><gtr:otherNames>Boultwood T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1523-7052</gtr:issn><gtr:outcomeId>545e3af1100432.74634662</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EA1F601B-ECA4-4A71-91CF-9A1F75394C31</gtr:id><gtr:title>Lithium-Catalyzed Thiol Alkylation with Tertiary and Secondary Alcohols: Synthesis of 3-Sulfanyl-Oxetanes as Bioisosteres.</gtr:title><gtr:parentPublicationTitle>Chemistry (Weinheim an der Bergstrasse, Germany)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c580814d2b42cae4f950b3cfad31b629"><gtr:id>c580814d2b42cae4f950b3cfad31b629</gtr:id><gtr:otherNames>Croft RA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0947-6539</gtr:issn><gtr:outcomeId>5a5789c10d8c67.90109996</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>34D4D3D7-FEE1-444D-8F4F-6EA094B1A086</gtr:id><gtr:title>Studies on the synthesis, stability and conformation of 2-sulfonyl-oxetane fragments.</gtr:title><gtr:parentPublicationTitle>Organic &amp; biomolecular chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/74cf5226e1195c16ad4c8ff5308f9e22"><gtr:id>74cf5226e1195c16ad4c8ff5308f9e22</gtr:id><gtr:otherNames>Morgan KF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1477-0520</gtr:issn><gtr:outcomeId>5675e21383495</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7A7A5BC4-2ED4-4CA4-946B-DBE4EEC327FF</gtr:id><gtr:title>Synthesis of NH-sulfoximines from sulfides by chemoselective one-pot N- and O-transfers.</gtr:title><gtr:parentPublicationTitle>Chemical communications (Cambridge, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5a23a5837f7693af8866ec7146e3875a"><gtr:id>5a23a5837f7693af8866ec7146e3875a</gtr:id><gtr:otherNames>Tota A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1359-7345</gtr:issn><gtr:outcomeId>588b5a75a47259.01101354</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BC99C7A9-3DF5-423B-97B6-D719CAB180FA</gtr:id><gtr:title>A molecular rotor for measuring viscosity in plasma membranes of live cells.</gtr:title><gtr:parentPublicationTitle>Chemical communications (Cambridge, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f18520a7abe53fe137fb35d5818e90fe"><gtr:id>f18520a7abe53fe137fb35d5818e90fe</gtr:id><gtr:otherNames>L?pez-Duarte I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1359-7345</gtr:issn><gtr:outcomeId>56dd8fb6ee9a34.16859261</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DAE5DCC9-FDDB-4CB0-9779-805B9DC0DCD7</gtr:id><gtr:title>Structurally Divergent Lithium Catalyzed Friedel-Crafts Reactions on Oxetan-3-ols: Synthesis of 3,3-Diaryloxetanes and 2,3-Dihydrobenzofurans.</gtr:title><gtr:parentPublicationTitle>Chemistry (Weinheim an der Bergstrasse, Germany)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c580814d2b42cae4f950b3cfad31b629"><gtr:id>c580814d2b42cae4f950b3cfad31b629</gtr:id><gtr:otherNames>Croft RA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0947-6539</gtr:issn><gtr:outcomeId>585d5786a333c5.08609654</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">EP/J001538/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects><gtr:researchSubject><gtr:id>60EBB420-734E-4DB5-B0F2-65A1115A27F8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Chemical synthesis</gtr:text></gtr:researchSubject></gtr:researchSubjects><gtr:researchTopics><gtr:researchTopic><gtr:id>454398F2-57A6-4959-8845-0F248CF4D5C4</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Chemical Synthetic Methodology</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>